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Purpose: We aimed to assess the associations of handgrip strength (HS) with cardiovascular and all-
cause mortality and whether adding data on HS to cardiovascular disease (CVD) risk factors is associated 
with improvement in CVD mortality prediction. 
Design: Handgrip strength was assessed in a population-based sample of 861 participants aged 61-74 
years at baseline. Relative HS was obtained by dividing the absolute value by body weight.  
Results: During a median (interquartile range) follow-up of 17.3 (12.6-18.4) years, 116 fatal coronary 
heart diseases (CHDs), 195 fatal CVDs, and 412 all-cause mortality events occurred. On adjustment for 
several risk factors, the hazard ratios (95% CIs) for fatal CHD, fatal CVD, and all-cause mortality were 
0.59 (0.37-0.95), 0.59 (0.41-0.86), and 0.66 (0.51-0.84) respectively comparing extreme tertiles of 
relative HS. Adding relative HS to a CVD mortality risk prediction model containing established risk 
factors did not improve discrimination or reclassification using Harrel’s C-index (C-index change: 
0.0034; p=0.65), integrated-discrimination-improvement (0.0059; p=0.20), and net-reclassification-
improvement (-1.31%; p=0.74); however, there was a significant difference in in -2 log likelihood 
(p<0.001). 
Conclusion: Relative HS is inversely associated with CHD, CVD and all-cause mortality events. Adding 
relative HS to conventional risk factors improves CVD risk assessment using sensitive measures of 
discrimination. 
 











• Handgrip strength assessment is simple, inexpensive and it takes only a few minutes to 
measure in clinical practice; however, its prognostic role for fatal cardiovascular outcomes 
on top of traditional risk factors in apparently healthy populations is uncertain. 
• In a population-based prospective cohort study, good handgrip strength adjusted for body 
weight was associated with lower risk of fatal cardiovascular outcomes and the 
associations remained consistent across several clinically relevant subgroups. 






















Cardiovascular diseases (CVDs) account for over 17 million deaths per year, hence remaining the leading 
cause of mortality globally.(1) Though  great strides have been made in the treatment and prevention of 
CVDs over the last few decades, deaths due to CVDs are increasing because of increased life expectancy 
of the population.(2) Physical activity is well established to prevent vascular disease as well as 
mortality.(3) Physical fitness, a strong predictor of future health status,(4) has cardiorespiratory fitness 
(CRF) and muscular fitness as its main components.(5) Cardiorespiratory and muscular fitness are 
becoming well recognized in the prevention of chronic disease including vascular disease and all-cause 
mortality.(4, 6-9) Muscular fitness comprises of muscular strength, muscular endurance and muscular 
power.(5) Among these components, it appears muscular strength is the most widely studied in terms of 
its relationship to health. Muscular strength is defined as the ability of a specific muscle or muscle group 
to generate force or torque.(5) Handgrip strength, commonly used as a typical measure of muscular 
strength, has been shown in several prospective studies to be inversely associated with CVD, cause-
specific mortality and all-cause mortality outcomes.(10-19) However, majority of these studies were 
based in selected populations, included only male or female participants, or had short-term follow-up 
durations, which could potentially introduce biases such as reverse causation. The assessment of handgrip 
strength is particularly easy to measure, is a low-cost measurement tool, and takes only a few minutes to 
measure. Whether handgrip strength could be a useful prognostic tool for adverse clinical outcomes when 
added on the top of common risk factors in apparently healthy and aging populations is not well known. 
Given the uncertainty in the evidence, our primary aim was to assess the nature and magnitude of the 
associations of relative handgrip strength with the risk of fatal CHD and CVD events, and all-cause 







addition of relative handgrip strength measurements to conventional cardiovascular risk factors could 
improve the prediction of CVD mortality.  
 
Materials and methods  
Study design and population 
This report was performed in accordance to the STROBE (STrengthening the Reporting of OBservational 
studies in Epidemiology) guidelines for reporting observational studies in epidemiology (Supplementary 
Table S1).(20) The study cohort employed for this analysis was part of the Kuopio Ischemic Heart 
Disease (KIHD) risk factor Study, a prospective population-based cohort study designed to investigate 
potential risk factors for atherosclerotic CVD and other related chronic disease outcomes.(21) The initial 
study participants comprised a representative sample of men recruited from the city of Kuopio and its 
surrounding rural communities in eastern Finland. These participants underwent re-examinations at 4 
years, 11 years and 20 years after baseline. During the 11-year follow-up examination, women were 
invited to join the study. This cohort was employed for the current analysis and initially comprised 2358 
invited participants (1007 men and 1351 women) who were aged 53 to 74 years at baseline.(22) Of the 
2072 participants found to be potentially eligible, 193 did not agree to participate, 66 did not respond to 
the invitation and 39 declined to provide informed consent, which left 1774 participants.(22) Baseline 
examinations were conducted from March 1998 to December 2001.(22) The current analysis included 861 
men and women who had complete information on handgrip strength, relevant covariates, and specified 
outcomes (Supplementary Table S2). The study protocol was approved by Research Ethics Committee 









Assessment of handgrip strength and relevant risk markers 
Handgrip strength was measured by a hand dynamometer (Martin-Balloon-Vigorimeter; Gebrüder 
Martin, Tuttlingen, Germany). Measurements were taken with the subjects standing in upright position 
and their arms parallel to their body. Two measurements were taken for the dominant hand and the mean 
of both values was used for analysis. One-minute resting gap was given between both handgrip 
measurements.  To minimize the effect of body weight on the magnitude of handgrip strength, values of 
handgrip strength were then divided by weight in kilograms to yield relative handgrip strength (in kg). 
The dynamometers were calibrated at the beginning of each testing. Blood sample collection procedures, 
assessment of lifestyle characteristics and physical measures, and measurement of blood-based markers 
have been described in detail in previous reports.(23) Before blood collection, participants fasted 
overnight and abstained from drinking alcohol for at least 3 days and from smoking for at least 12 hours. 
Blood lipids including total cholesterol and high-density lipoprotein cholesterol (HDL-C) were measured 
enzymatically (Boehringer Mannheim, Mannheim, Germany) from fresh serum samples after combined 
ultracentrifugation and precipitation.(24) Fasting plasma glucose was estimated by the glucose 
dehydrogenase method (Merck, Darmstadt, Germany) after protein precipitation by trichloroacetic 
acid.(24) Serum high sensitivity C-reactive protein (hsCRP) measurements were made with an 
immunometric assay (Immulite High Sensitivity C-Reactive Protein Assay; DPC, Los Angeles, CA, 
USA). Resting blood pressure was measured between 8 and 10 a.m. using a random-zero 
sphygmomanometer (Hawskley, UK) after 5 and 10 minutes of rest in a seated position.(25) Self-
administered questionnaires were used to assess baseline socio-demographic and lifestyle characteristics, 
prevalent medical conditions and use of medications.(26) The energy expenditure of physical activity was 
assessed from a validated 12-month leisure-time physical activity questionnaire.(27) This detailed 







middle-aged Finnish men. For the type of physical activity performed, participants were asked to 
document the frequency (number of sessions per month), average duration (hours and minutes per 
session) and intensity.(28) Energy expenditure was measured for each physical activity by multiplying the 
metabolic index of activity (in metabolic equivalent*hour/week) by body weight in kilograms. Body mass 
index (BMI) was calculated by dividing weight measured in kilograms by the square of height in meters.  
 
Ascertainment of outcomes 
Outcomes evaluated included fatal CHD and CVD outcomes as well as all-cause mortality. We included 
all deaths that occurred from study enrollment through to 31st December 2017. Participants are under 
continuous annual surveillance for the occurrence of new CVD events, which include incident cases and 
deaths. There were no losses to follow-up. Information on outcomes was ascertained by computerized 
data linkage to the Finnish national hospital discharge registry and death certificate registers. Other 
sources of information were based on review of all available hospital records, questionnaires administered 
to health workers, wards of healthcare centres or hospitals, interviews with informants and medico-legal 
reports. Coronary heart disease and CVD deaths were coded using the International Statistical 
Classification of Diseases, 10th Revision (ICD-10), codes. All-cause mortality outcomes comprised of any 
deaths including CVD and CHD deaths. All documents were checked in detail by two physicians. The 




Baseline characteristics were presented as means (standard deviation, SD) or medians (interquartile range, 







and sex-adjusted partial correlation coefficients were estimated to assess the cross-sectional associations 
of relative handgrip strength with several risk markers. Hazard ratios (HRs) with 95% confidence 
intervals (CIs) for fatal CHD and CVD and all-cause mortality were calculated using Cox proportional 
hazard models after confirmation of no major departure from the proportionality of hazards assumptions 
using Schoenfeld residuals. The shape of the relationship between relative handgrip strength and each 
outcome was assessed by calculating HRs within quartiles of baseline relative handgrip strength, which 
were then plotted against mean values of relative handgrip strength within each quartile. Floating 
variances were used to calculate 95% CIs for the log hazard ratio in each group (including the reference 
group), which allowed for comparisons across the groups irrespective of the arbitrarily chosen reference 
category (bottom quartile).(29) We modeled relative handgrip strength as both continuous [per standard 
deviation (SD) increase] and categorical (tertiles) exposures; given the relatively low sample size, tertile 
cutoffs were employed for the assessment of associations to ensure adequate power in each exposure 
category. Hazard ratios were adjusted for in two models: (i) age and sex and (ii) plus systolic blood 
pressure, total cholesterol, HDL-C, smoking status, prevalent CHD history of diabetes mellitus, resting 
heart rate, and energy expenditure of total LTPA. Subgroup analyses were performed using tests of 
interaction to assess statistical evidence of any differences in hazard ratios across levels/categories of pre-
specified individual level characteristics. To minimize biases due to reverse causation, sensitivity analysis 
excluded the first two years of follow-up.  
To evaluate whether adding information on relative handgrip strength to conventional cardiovascular 
risk factors would be associated with an improvement in CVD mortality risk prediction and if relative 
handgrip strength helps to correctly classify participants into predicted CVD risk categories, we 
calculated measures of discrimination for censored time-to-event data (Harrell’s C-index (30)) and 







strength, two CVD mortality risk prediction models were fitted: one model based on traditional risk 
factors (i.e., age, SBP, history of diabetes, total cholesterol, HDL-C, and smoking) included in well-
known CVD risk algorithms (such as the Framingham Risk Score (FRS)(33) and the Pooled Cohort 
equations(34))  and the second model containing the traditional risk factors plus relative handgrip 
strength. Reclassification was assessed using the net-reclassification-improvement (NRI)(31, 32) and 
integrated-discrimination-improvement (IDI)(31) by comparing the model containing conventional risk 
factors  to the predicted risk from the model containing conventional risk factors plus relative handgrip 
strength. Reclassification analysis was based on predicted 10-year CVD mortality risk categories of low 
(< 1%), intermediate (1 to < 5%), and high (≥ 5%) risk as previously reported.(35) Finally, we calculated 
the integrated discrimination improvement (IDI), which integrates the NRI over all possible cutoffs of 
predicted risk and mathematically corresponds to the difference in discrimination slopes of the 2 models 
in comparison.(31) Given that Harrell’s C-index is based on ranks rather than on continuous data, it can 
be insensitive in detecting differences.(36, 37) To avoid discarding potential biomarkers that can be used 
in risk prediction, sensitive risk discrimination methods such as the -2 log likelihood test (likelihood ratio 
test) have been recommended.(36, 37)  Therefore, in addition to Harrel’s C-index, we tested for 
differences in the -2 log likelihood of prediction models with and without inclusion of calprotectin. All 
statistical analyses were conducted using Stata version MP 16 (Stata Corp, College Station, Texas). 
 
Results 
Baseline characteristics and correlates of handgrip strength 
The mean (SD) age of study participants at baseline was 69 (3) years and 47.3% comprised of males. The 
mean (SD) value of relative handgrip strength at baseline was 1.03 (0.34) kpa/kg (Table 1). Weak to 







plasma glucose and hsCRP. Relative handgrip strength was weakly and positively correlated with HDL-
C. During a median (IQR) follow-up of 17.3 (12.6-18.4) years (13,055 person-years at risk), a total of 116 
fatal CHDs, 195 fatal CVDs, and 412 all-cause mortality events were recorded. 
 
Relative handgrip strength and risk of outcome events 
In analyses adjusted for several established and emerging risk factors (age, sex, systolic blood pressure, 
total cholesterol, HDL-C, smoking status, prevalent CHD history of diabetes mellitus, resting heart rate, 
and energy expenditure of total LTPA), relative handgrip strength was continually and inversely 
associated with fatal CHD, fatal CVD, and all-cause mortality, and these were potentially consistent with 
curvilinear shapes (Figure 1). Table 2 shows the associations of relative handgrip strength with each 
outcome. The age- and sex-adjusted HRs (95% CIs) per 1 SD increase in relative handgrip strength for 
fatal CHD, fatal CVD, and all-cause mortality were 0.61 (0.46-0.79), 0.67 (0.54-0.82), and 0.79 (0.69-
0.91) respectively. These were only minimally attenuated to 0.65 (0.49-0.85), 0.69 (0.56-0.86), and 0.81 
(0.70-0.93) respectively after adjustment for established and emerging risk factors. In analyses that 
compared the top versus bottom thirds of relative handgrip strength values, the age-and sex-adjusted HRs 
(95% CIs) for fatal CHD, fatal CVD, and all-cause mortality were 0.51 (0.32-0.83), 0.55 (0.38-0.79), and 
0.64 (0.50-0.82) respectively.  On multivariable adjustment, the corresponding HRs (95% CIs) were 0.59 
(0.37-0.95), 0.59 (0.41-0.86), and 0.66 (0.51-0.84) respectively. The associations did not vary 
significantly by levels or categories of several clinically relevant characteristics (Figures 2-4). The 
associations of relative handgrip strength with outcomes remained consistent in analyses that excluded the 









Handgrip strength and CVD mortality risk prediction 
A CVD mortality risk prediction model containing conventional risk factors (age, SBP, history of 
diabetes, total cholesterol, HDL-C, and smoking) yielded a C-index of 0.7202 (95% CI: 0.6838 to 0.7566; 
p<0.001). On addition of information on relative handgrip strength to this prognostic model, there was a 
non-significant increase in the C-index by 0.0034 (95% CI: -0.01128 to 0.0181; p=0.65). When 
investigating differences in the -2 log likelihood of the risk score with and without inclusion of handgrip 
strength, the -2 log likelihood was significantly improved on addition of information on handgrip strength 
to the model (p for comparison<0.001). There was no significant improvement in the classification of 
participants into predicted 10-year CVD mortality risk categories (NRI: -1.31%, -8.90 to 6.27%; p=0.74). 
The IDI was 0.0058 (-0.0031 to 0.0148; p = 0.20). 
 
Discussion 
Based on a general population sample of Finnish men and women, the current findings show that relative 
handgrip strength is continuously and inversely associated with the risk of fatal CHD and CVD, and all-
cause mortality in analyses adjusted for several established and emerging cardiovascular risk factors.  
There were mostly weak to modest inverse correlations of relative handgrip strength with several 
cardiovascular risk markers. The associations of relative handgrip strength with outcomes remained 
generally similar across several clinically relevant subgroups. With regard to assessment of the clinical 
value of handgrip strength, the addition of information on relative handgrip strength to a risk model 
containing traditional risk factors did not improve discrimination of CVD mortality risk using Harrell’s 
C-index; however, there was a significant improvement on using the -2 log likelihood method, a more 







The inverse associations demonstrated between handgrip strength (an easily available objective and 
reproducible measure in clinical practice) and vascular mortality outcomes are consistent with previous 
findings on this topic.(10-14) It has been suggested that Hand grip strength may enhance risk prediction 
for all-cause mortality on top of the risk prediction seen with age or sex.(38, 39) A recent study also 
showed that handgrip strength improved the prediction ability of all-cause mortality and cardiovascular 
mortality, using an office based risk score comprising of common risk factors such as age, sex, diabetes, 
body mass index, systolic blood pressure, and smoking.(40) However, none of these studies have shown 
whether the addition of handgrip strength to an established CVD risk score, including age, SBP, history of 
diabetes, total cholesterol, HDL-C, and smoking, improves risk prediction accuracy of fatal 
cardiovascular outcomes. A recent UK Biobank study proposed in population-based screening settings 
where demanding physical fitness assessment tools may not be feasible, the measurement of handgrip 
strength may add clinical utility over existing risk prediction scores.(40) Earlier findings from the 
Prospective Urban Rural Epidemiology (PURE) study showed that grip strength has a stronger 
association with cardiovascular mortality than with incident CVD, with an effect-size that was twice as 
large for cardiovascular death as for CVD.(16) This finding implies that low hand grip strength is 
associated with increased susceptibility to cardiovascular mortality especially in people who may develop 
chronic CVDs.  However, a population-based study among participants from Lausanne (CoLaus) 
suggested that low hand grip strength was not related to incident cardiovascular events and overall 
morality after multivariate adjustment.(41) 
Cardiorespiratory fitness largely reflects functional status,(42-44) whereas handgrip strength is a 
measure of upper body (arms) muscle strength. Though it has been suggested that handgrip strength may 
be a proxy for overall muscle strength, it has been recently shown that it cannot accurately measure all 







provides a valid index of overall limb muscle strength. There is some evidence to suggest that resistance 
muscle training interventions can increase in glycolytic capacity and up-regulate insulin action and 
capacity for glucose utilization in muscles.(46) Structured resistance training promotes muscle function 
and alleviate the levels of cardiometabolic risk factors.(46) There is growing evidence that objective 
measures of physical performance such as handgrip strength, sitting-rising and standing balance tests not 
only characterize physical capability but also act as markers of general health status.(47) Handgrip 
strength decrease is also an indicator of frailty and age-associated loss of muscle mass(17) which appears 
to be inevitable and is likely to be the most significant contributing factor to the decline in muscle 
strength. Frailty is usually quantified by the degree of impairment in functional reserve across multiple 
organ systems and is often associated with fatigue, reduced muscle strength, and high susceptibility to 
chronic disease. In addition, associations between these measures of frailty and functional capacity 
(muscle strength) and cause specific mortality outcomes, may help to clarify the pathways underlying the 
associations between muscle fitness and CVDs. The muscle is a paracrine and exocrine organ. Myokines 
may act in autocrine, paracrine, and endocrine manner and regulate several processes associated with 
physical frailty.(48, 49) The release of myokines from skeletal muscle preserves or augments 
cardiovascular function. Increased muscle strength may provide capabilities for more active life-styles 
that are related to a lower CVD risk. Elucidating the proposed biological mechanistic pathways between 
poorer functional capacity such muscle strength and fatal CVD events may help in the development of 
more effective muscle training interventions. The assessment of grip strength can be recommended as a 











Findings from our risk prediction analysis using the more sensitive -2 log likelihood method shows that 
handgrip strength urine augments CVD mortality risk prediction beyond that of traditional risk factors, 
and the observation of a graded association suggests that handgrip strength is potentially suitable for 
population-level risk assessment. Handgrip strength may be a potential risk assessment tool in general or 
specialized clinical setting to identify patients at high risk for worse outcomes, but more evaluation is 
needed. Handgrip strength, as a predictive biomarker of specific outcomes, can be improved through 
regular resistance training to improve and maintain muscular fitness. 
 
Strengths and limitations 
Although previous prospective cohort studies have investigated the associations of handgrip strength with 
fatal vascular outcomes, this is the first prospective evaluation of the associations between relative 
handgrip strength and the risk of cardiovascular and all-cause mortality outcomes as the investigation of 
the potential utility of relative handgrip strength for CVD mortality risk prediction assessment. The cohort 
had a long follow-up period and no losses to follow-up were recorded, given that study participants 
undergo annual monitoring and outcomes are checked using well-linked established databases.(7, 50) The 
sample was a nationally representative population-based cohort of middle-aged to elderly Caucasian men 
and women, which makes it possible to generalize the results in Northern European populations. Because 
body size is a key factor that explains muscle strength results, we used body weight adjusted values as a 
main handgrip strength exposure. We employed comprehensive analyses which included adjustment for 
several lifestyle and biological markers with underlying disease status, testing for effect modification by 
several relevant clinical subgroups, and accounting for reverse causation bias. Our risk prediction 







and analyses, there are limitations which merit mention. The findings were based on older men and 
women, hence cannot be generalised to other age groups. The addition of information on relative 
handgrip strength to the risk model did not improve CVD mortality risk discrimination using Harrell’s C-
index and this could be attributed to the fact that changes in C-index are largely dependent on the risk 
model, follow-up time and outcome events that have been used. Furthermore, Harrell’s C-index can be 
insensitive in detecting differences because it is based on ranks.(36, 37) Our assessment of handgrip 
strength did not employ testing procedures recommended by the American Society of Hand Therapists 
(ASHT)(51) or the Southampton protocol,(52) which could have introduced biases in our findings. 
Handgrip strength assessment was conducted in accordance with the KIHD study protocol and utilised the 
Martin-Balloon-Vigorimeter, which was considered to be appropriate for the study population. Evidence 
suggests the Martin Vigorimeter is a reliable and practical tool for assessing handgrip strength in the 
elderly population.(53) The substantial heterogeneity between the handgrip strength test protocols used in 
studies on hand grip strength and outcome studies, has created difficulties in drawing comparative and 
consistent conclusions.(54) Though several potential confounders were taken into account, there is a 
potential for residual confounding, which is quite likely for observational study designs. Though we took 
into account the level of physical activity in our analyses, data on objectively assessed CRF was not 
available for all participants and hence could not be used. The observed associations could be 
underestimates because of the inability to correct for regression dilution bias, as the associations were 
based on baseline assessments of relative handgrip strength. Due to aging, disease, and changes in health 











This population-based prospective study shows inverse and continuous associations of relative handgrip 
strength with cardiovascular and all-cause mortality outcomes. Adding relative handgrip strength to 
conventional risk factors improves CVD mortality risk assessment using more sensitive measures of 
discrimination. The use of handgrip strength as a predictor of cardiovascular health status and outcomes 
requires further investigation. It would also be relevant to ascertain if physical exercise and specific 
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Figure 1. Hazard ratios for fatal coronary heart disease, fatal cardiovascular disease, and all-cause 










































































Hazard ratios were adjusted for age, gender, systolic blood pressure, total cholesterol, high-density lipoprotein 
cholesterol, smoking status, prevalent coronary heart disease, history of diabetes mellitus, resting heart rate, and 









Figure 2. Hazard ratios for fatal coronary heart disease by several participant level characteristics 
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Hazard ratios compared top versus bottom thirds of relative handgrip strength and were adjusted for age, gender, 
systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, smoking status, prevalent coronary 
heart disease, history of diabetes mellitus, resting heart rate, and physical activity; CHD, coronary heart disease; CI, 
confidence interval; HDL, high-density lipoprotein; HR, hazard ratio; LTPA, leisure-time physical activity; *, p-
value for interaction; cut-offs for age, body mass index, systolic blood pressure, total cholesterol, HDL cholesterol, 








Figure 3. Hazard ratios for fatal cardiovascular disease by several participant level characteristics 
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Hazard ratios compared top versus bottom thirds of relative handgrip strength and were adjusted for age, gender, 
systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, smoking status, prevalent coronary 
heart disease, history of diabetes mellitus, resting heart rate, and physical activity; CHD, coronary heart disease; CI, 
confidence interval; HDL, high-density lipoprotein; HR, hazard ratio;  
LTPA, leisure-time physical activity; *, p-value for interaction; cut-offs for age, body mass index, systolic blood 









Figure 4. Hazard ratios for all-cause mortality by several participant level characteristics 
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Hazard ratios compared top versus bottom thirds of relative handgrip strength and were adjusted for age, gender, 
systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, smoking status, prevalent coronary 
heart disease, history of diabetes mellitus, resting heart rate, and physical activity; CHD, coronary heart disease; CI, 
confidence interval; HDL, high-density lipoprotein; HR, hazard ratio;  
LTPA, leisure-time physical activity; *, p-value for interaction; cut-offs for age, body mass index, systolic blood 













Mean (SD), median 
(IQR), or n (%) 
Partial correlation 
r (95% CI)a 
Relative handgrip strength (kPa/kg) 1.03 (0.34) - 
   
Questionnaire/Prevalent conditions   
Age at survey (years) 69 (3) -0.13 (-0.19, -0.06)* 
Males 407 (47.3) - 
History of type 2 diabetes 83 (9.6) - 
Current smokers 81 (9.4) - 
History of CHD 308 (35.8) - 
   
Physical measurements   
BMI (kg/m2) 27.9 (4.3) -0.41 (-0.46, -0.35)*** 
SBP (mmHg) 138 (18) 0.02 (-0.05, 0.09) 
DBP (mmHg) 80 (9) 0.03 (-0.04, 0.10) 
Energy expenditure of total LTPA (kcal/day) 377.4 (226.1-646.3) -0.01 (-0.08, 0.06) 
Resting heart rate (bpm) 62.5 (9.8) 0.06 (-0.01, 0.13) 
   
Blood-based markers   
Total cholesterol (mmol/l) 5.44 (0.94) 0.02 (-0.05, 0.08) 
HDL-C (mmol/l) 1.24 (0.32) 0.10 (0.03, 0.16)*** 
Fasting plasma glucose (mmol/l) 5.18 (1.32) -0.08 (-0.14, -0.01)* 
High-sensitivity CRP 1.58 (0.79-3.23) -0.19 (-0.25, -0.12)*** 
 
BMI, body mass index; CHD, coronary heart disease; CI, confidence interval; CRP, C-reactive protein; DBP, diastolic blood pressure;  
HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; LTPA, leisure-time physical activity; SD, standard deviation;  










Table 2. Associations of handgrip strength with fatal coronary heart disease, fatal cardiovascular disease, 




Fatal CHD  Fatal CVD  All-cause 
mortality 
 
 116 cases  195 cases  412 cases  
 HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Age- and sex-adjusted       
Per 1 SD increase 0.61 (0.46-0.79) < 0.001 0.67 (0.54-0.82) < 0.001 0.79 (0.69-0.91) < 0.001 
Tertile 1 (0.27-0.90) 1 [Reference]  1 [Reference]  1 [Reference]  
Tertile 2 (0.91-1.10) 0.66 (0.43-1.01) 0.057 0.70 (0.51-0.98) 0.035 0.74 (0.59-0.92) 0.008 
Tertile 3 (1.11-7.31) 0.51 (0.32-0.83) 0.006 0.55 (0.38-0.79) 0.001 0.64 (0.50-0.82) < 0.001 
Multivariate-adjusted*       
Per 1 SD increase 0.65 (0.49-0.85) 0.002 0.69 (0.56-0.86) 0.001 0.81 (0.70-0.93) 0.003 
Tertile 1 (0.27-0.90) 1 [Reference]  1 [Reference]  1 [Reference]  
Tertile 2 (0.91-1.10) 0.68 (0.44-1.05) 0.082 0.70 (0.50-0.97) 0.033 0.74 (0.59-0.93) 0.011 
Tertile 3 (1.11-7.31) 0.59 (0.37-0.95) 0.029 0.59 (0.41-0.86) 0.006 0.66 (0.51-0.84) 0.001 
 
CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; SD, standard deviation 
*, Hazard ratios are adjusted for age, gender, systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, 










Supplementary Table S1 STROBE 2007 Statement—Checklist of items that should be included in 
reports of cohort studies 
Supplementary Table S2 Participant flow 
Supplementary Table S3 Associations of handgrip strength with fatal coronary heart disease, fatal 
cardiovascular disease, and all-cause mortality on exclusion of the first two 










Supplementary Table S1: STROBE 2007 Statement—Checklist of items that should be included in reports 





Reported on page 
# 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title 
or the abstract 
Page 1 
(b) Provide in the abstract an informative and balanced summary of 
what was done and what was found 
Page 2 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation 
being reported 
Page 3 
Objectives 3 State specific objectives, including any prespecified hypotheses Page 3 
Methods  
Study design 4 Present key elements of study design early in the paper Study design and 
population 
 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
Study design and 
population 
 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection 
of participants. Describe methods of follow-up 
Study design and 
population 
 
(b) For matched studies, give matching criteria and number of exposed 
and unexposed 
Study design and 
population 
 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if applicable 
Assessment of 
handgrip strength 





8*  For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe comparability of 
assessment methods if there is more than one group 
Assessment of 
handgrip strength 
and relevant risk 
markers 
 
Bias 9 Describe any efforts to address potential sources of bias Statistical analysis 
 
Study size 10 Explain how the study size was arrived at Statistical analysis 
 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why 
Statistical analysis 
 










(b) Describe any methods used to examine subgroups and interactions Statistical analysis 
 
(c) Explain how missing data were addressed Not applicable 
(d) If applicable, explain how loss to follow-up was addressed Not applicable 




Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included 
in the study, completing follow-up, and analysed 
Supplementary 
Table S3 
  (b) Give reasons for non-participation at each stage Supplementary 
Table S3 
  (c) Consider use of a flow diagram Supplementary 
Table S3 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, 
social) and information on exposures and potential confounders 
Results; Tables 1  
  (b) Indicate number of participants with missing data for each variable 
of interest 
 
  (c) Summarise follow-up time (eg, average and total amount) Results 
Outcome data 15* Report numbers of outcome events or summary measures over time Results 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included 
Results; Table 2 
  (b) Report category boundaries when continuous variables were 
categorized 
Results; Table 2 
  (c) If relevant, consider translating estimates of relative risk into 
absolute risk for a meaningful time period 
 
Other analyses 17 Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses 
Results; Figure 2-4 
Discussion 
   
Key results 18 Summarise key results with reference to study objectives Discussion - 
Summary of main 
findings 
Limitations    
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and 
other relevant evidence 
Discussion 
Generalisability 21 Discuss the generalisability (external validity) of the study results Discussion 
Other information 
   
Funding 22 Give the source of funding and the role of the funders for the present 
study and, if applicable, for the original study on which the present 









Supplementary Table S2: Participant flow 
Remaining participants
n = 1774
(920 women and 854 men)
Data on handgrip strength, risk factors 
and outcomes were available for 861
participants 
(454 women and 407 men)
Baseline examination
Years 1998−2001
Invited, n = 2358
(1351 women and 1007 men)
- Death 72
- Severe illness 135
- Migrated 20
- Unknown address 5
Eligible, n = 2072
(1173 women and 899 men)
- Refused 193
- No contact 66 












Supplementary Table S3: Associations of handgrip strength with fatal coronary heart disease, 





Fatal CHD  Fatal CVD  All-cause mortality  
 111 cases  187 cases  400 cases  
 Hazard ratio (95% CI) p-value Hazard ratio (95% 
CI) 
p-value Hazard ratio (95% 
CI) 
p-value 
Age- and sex-adjusted       
Per 1 SD increase 0.59 (0.45-0.78) < 0.001 0.66 (0.54-0.81) < 0.001 0.79 (0.69-0.91) < 0.001 
Tertile 1 (0.27-0.90) 1 [Reference]  1 [Reference]  1 [Reference]  
Tertile 2 (0.91-1.10) 0.63 (0.41-0.98) 0.039 0.67 (0.48-0.94) 0.019 0.73 (0.58-0.92) 0.008 
Tertile 3 (1.11-7.31) 0.48 (0.29-0.78) 0.003 0.54 (0.37-0.78) 0.001 0.65 (0.50-0.83) 0.001 
Multivariate-adjusted*       
Per 1 SD increase 0.64 (0.48-0.85) 0.002 0.69 (0.55-0.85) 0.001 0.81 (0.70-0.93) 0.004 
Tertile 1 (0.27-0.90) 1 [Reference]  1 [Reference]  1 [Reference]  
Tertile 2 (0.91-1.10) 0.65 (0.42-1.01) 0.053 0.66 (0.47-0.93) 0.016 0.73 (0.58-0.92) 0.009 
Tertile 3 (1.11-7.31) 0.56 (0.34-0.92) 0.022 0.59 (0.40-0.86) 0.006 0.67 (0.52-0.87) 0.002 
 
CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; SD, standard deviation 
*, Hazard ratios are adjusted for age, gender, systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, 
smoking status, prevalent coronary heart disease, history of type 2 diabetes mellitus, resting heart rate, and physical activity 
 
 
 
 
